There are an estimated 26 million Americans with chronic kidney disease (CKD). Early diagnosis and treatment are the only cost-effective means to reverse this growing problem. NIH recognizes the challenge to diagnose CKD early during its initiation and development phases in order to prevent further renal damage, reduce cardiovascular risk, and minimize the economic impact of CKD. Currently, two complimentary tests - estimated GFR (eGFR) and urine albumin-to-creatinine ratio (UACR) - are used to identify CKD and are effective once the onset of disease has occurred. We will produce a new ELISA for CKD to be employed as a diagnostic test based upon the use of a novel biomarker that reflects critical events in the pathophysiology of kidney disease. Preliminary results suggest that our CKD-ASSAY could replace or compliment both predicate assays. Further, the specificity and reproducibility of the results may reduce or eliminate the need for repeat testing. Aside from increased convenience and reduced time to treatment, this may mean that the cost of screening for CKD may be greatly reduced. Our CKD-ASSAY would give physicians the ability to evaluate patients that have been recently diagnosed with hypertension, diabetes, or a family history of CKD. In Phase I, we evaluated the feasibility and proof-of principal of this test and found that the prototype assay in both at-risk populations was highly sensitive and specific. In Phase II, we confirmed the specificity of our CKD-ASSAY, established concordance with other assays, and looked for other factors that might have impacted on assay performance. We request Phase IIB support so that we can prepare cGMP kits, perform the pivotal clinical evaluations, submit our 510(k) application to the FDA, and prepare for commercial launch.

Public Health Relevance

Chronic Kidney Disease affects nearly 26 million people in the United States, which places them at higher risk of cardiovascular disease, hemodialysis, and end stage renal disease. We will develop an assay for identification of people with advanced kidney disease that are under-diagnosed by current methods and to aid physicians in earlier treatment and better assessment of chronic kidney disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44DK089892-06
Application #
8984464
Study Section
Special Emphasis Panel (ZRG1-DKUS-L (11))
Program Officer
Moxey-Mims, Marva M
Project Start
2010-09-20
Project End
2018-06-30
Budget Start
2015-08-10
Budget End
2016-06-30
Support Year
6
Fiscal Year
2015
Total Cost
$989,285
Indirect Cost
Name
Sequela
Department
Type
DUNS #
189577070
City
Pewee Valley
State
KY
Country
United States
Zip Code
40056
Rozenfeld, Julia; Tal, Osnat; Kladnitsky, Orly et al. (2013) Pendrin, a novel transcriptional target of the uroguanylin system. Cell Physiol Biochem 32:221-37
Rozenfeld, Julia; Tal, Osnat; Kladnitsky, Orly et al. (2012) The pendrin anion exchanger gene is transcriptionally regulated by uroguanylin: a novel enterorenal link. Am J Physiol Renal Physiol 302:F614-24
Rozenfeld, Julia; Efrati, Edna; Adler, Lior et al. (2011) Transcriptional regulation of the pendrin gene. Cell Physiol Biochem 28:385-96